Olympus Corp Ord (OCPNF) Q1 2027 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Olympus Corp..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.331 -- 00:00:04.672 Now we would like to move on to Q&A. 00:00:04.813 -- 00:00:07.334 My first question 00:00:07.334 -- 00:00:11.956 is about GI endoscopy doing very well in the United States. 00:00:11.956 -- 00:00:15.457 Eat off scope penetration 00:00:15.658 -- 00:00:21.721 for high-end customers. So what is the penetration rate, adoption rate? 00:00:21.721 -- 00:00:24.021 In other words, 00:00:24.903 -- 00:00:29.013 It's pretty strong in the first half, but do you think the trend will continue in the 00:00:29.013 -- 00:00:32.233 second half of the year? That's my first question. 00:00:32.233 -- 00:00:36.054 Thank you for the question, and I'll have Keith 00:00:36.295 -- 00:00:41.718 jump in here in a minute. But you're right to point out that our EDOF scope 00:00:41.718 -- 00:00:45.860 and our EVUS X1 adoption has been strong. 00:00:45.860 -- 00:00:50.983 We believe there's upside, continued upside to that penetration, 00:00:50.983 -- 00:00:54.164 not just in North America, but Keith, as the question was about North America, you want 00:00:54.164 -- 00:00:55.785 to talk about North America specifically? 00:00:55.785 -- 00:01:00.788 Yeah, look, EVAS X1 represents the leading edge of our innovation 00:01:00.788 -- 00:01:02.788 strategy. 00:01:03.050 -- 00:01:08.573 I would say in the U.S. we're still kind of early to mid innings in terms of our penetration 00:01:08.573 -- 00:01:12.795 rates. You know, 00:01:13.056 -- 00:01:18.259 EMEA and Japan are a little bit further along, but there's still multiple years of runway 00:01:18.259 -- 00:01:22.222 ahead in the United States, particularly as we extend the Edovscope family. 00:01:22.222 -- 00:01:25.363 Thank you. Okay, my second question. 00:01:44.572 -- 00:01:47.333 R&D expenditure 00:01:47.515 -- 00:0...